Alkermes - Public Comps and Valuation Multiples

Alkermes Overview

About Alkermes

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

Founded

2011

HQ

Employees

1.8K+

Website

alkermes.com

Sectors

Biopharmaceuticals
Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $1.4B

LTM EBITDA $369M

EV

$4.1B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Alkermes Financials

As of September 2025, Alkermes reported last 12-month revenue of $1.4B and EBITDA of $369M.

In the same period, Alkermes generated $1.2B in LTM gross profit and $246M in net income.

See Alkermes valuation multiples based on analyst estimates

Alkermes P&L

In the most recent fiscal year, Alkermes reported revenue of $1.6B and EBITDA of $495M.

Alkermes expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Alkermes valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$1.4B	XXX	$1.6B	XXX	XXX	XXX
Gross Profit	$1.2B	XXX	$1.3B	XXX	XXX	XXX
Gross Margin	86%	XXX	84%	XXX	XXX	XXX
EBITDA	$369M	XXX	$495M	XXX	XXX	XXX
EBITDA Margin	25%	XXX	32%	XXX	XXX	XXX
EBIT	$261M	XXX	$421M	XXX	XXX	XXX
EBIT Margin	18%	XXX	27%	XXX	XXX	XXX
Net Profit	$246M	XXX	$367M	XXX	XXX	XXX
Net Margin	17%	XXX	24%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Alkermes including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $1.4B. EBITDA for the last twelve months was $369M. In the most recent fiscal year, Alkermes achieved $1.6B in revenue and $495M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$1.4B	Analyst estimates available to subscribers	$1.6B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$1.2B	Analyst estimates available to subscribers	$1.3B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	85.6% gross margin	Analyst estimates available to subscribers	84.2% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$369M	Analyst estimates available to subscribers	$495M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	25.5% EBITDA margin	Analyst estimates available to subscribers	31.8% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$261M	Analyst estimates available to subscribers	$421M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	18.0% EBIT margin	Analyst estimates available to subscribers	27.0% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$246M	Analyst estimates available to subscribers	$367M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	17.0% net profit margin	Analyst estimates available to subscribers	23.6% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Alkermes

This financial data table provides comprehensive performance metrics for Alkermes, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Alkermes generated $1.4B in revenue over the last twelve months.
The company achieved $369M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $1.2B.
Net income over the last twelve months reached $246M.

Fiscal Year Performance

In the most recent fiscal year, Alkermes reported $1.6B in total revenue.
Fiscal year EBITDA was $495M.
The company maintained a gross profit margin of 84.2% in the most recent fiscal year.
EBITDA margin for the fiscal year was 31.8%.
Net profit margin reached 23.6% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Alkermes. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Alkermes Stock Performance

Alkermes has current market cap of $5.0B, and EV of $4.1B.

Market Cap Evolution

Alkermes Stock Data

As of October 17, 2025, Alkermes's stock price is $30.

See Alkermes trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$4.1B	$5.0B	XXX	XXX	XXX	XXX	$1.86

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Alkermes Valuation Multiples

Alkermes's trades at 2.6x EV/Revenue multiple, and 8.2x EV/EBITDA.

See valuation multiples for Alkermes and 15K+ public comps

Alkermes Financial Valuation Multiples

As of October 17, 2025, Alkermes has market cap of $5.0B and EV of $4.1B.

Equity research analysts estimate Alkermes's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Alkermes has a P/E ratio of 20.3x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$5.0B	XXX	$5.0B	XXX	XXX	XXX
EV (current)	$4.1B	XXX	$4.1B	XXX	XXX	XXX
EV/Revenue	2.8x	XXX	2.6x	XXX	XXX	XXX
EV/EBITDA	11.0x	XXX	8.2x	XXX	XXX	XXX
EV/EBIT	15.5x	XXX	9.6x	XXX	XXX	XXX
EV/Gross Profit	3.3x	XXX	n/a	XXX	XXX	XXX
P/E	20.3x	XXX	13.6x	XXX	XXX	XXX
EV/FCF	10.1x	XXX	10.0x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Alkermes Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Alkermes Margins & Growth Rates

Alkermes's last 12 month revenue growth is -1%

Alkermes's revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $0.5M for the same period.

Alkermes's rule of 40 is 31% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Alkermes's rule of X is 24% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Alkermes and other 15K+ public comps

Alkermes Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	-1%	XXX	-4%	XXX	XXX	XXX
EBITDA Margin	25%	XXX	32%	XXX	XXX	XXX
EBITDA Growth	-5%	XXX	-18%	XXX	XXX	XXX
Rule of 40	31%	XXX	31%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	24%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.9M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.5M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	29%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	16%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	57%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial